title: [Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors].
abstract: (18)F-FDOPA is an amino acid analogue used to evaluate presynaptic dopaminergic activity, which has aroused great interest in neuro-oncology. We have evaluated five (18)F-FDOPA PET studies of patients referred for study of parkinsonian syndrome. Two subjects had previously treated high-grade brain tumors, one nonspecific brain injury, and 2 subjects presented unexpected tumoral lesions. For all lesions SUVmax, time to SUVmax and tumor-to-normal grey matter SUVmax rate (T/N) were calculated, and 90 minutes (18)F-FDOPA kinetics were analyzed. Tumor lesions corresponded to three malignant neurocytomas, one meningioma, one pineocytoma and one intrasinusal hemangioma. Both malignant and benign tumors exhibited high uptake of (18)F-FDOPA well above the normal cortex. However, the analysis of the curve uptake displayed characteristic patterns that facilitate the characterization of tumor lesions. A dual phase maximum uptake was observed, with an early 10 minutes uptake in malignant lesions, and a late 60 to 90 minutes uptake in benign or low grade lesions.
authors.affiliation: Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: González-Forero
authors.forename: E
authors.initials: E
authors.lastname: Prieto
authors.forename: I
authors.initials: I
authors.lastname: Domínguez
authors.forename: C
authors.initials: C
authors.lastname: Vigil
authors.forename: I
authors.initials: I
authors.lastname: Peñuelas
authors.forename: J
authors.initials: J
authors.lastname: Arbizu
mesh_terms: D000368:Aged; D001932:Brain Neoplasms / Q000150:complications / Q000000981:diagnostic imaging* / Q000628:therapy; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D005462:Fluorine Radioisotopes / Q000493:pharmacokinetics; D005626:Frontal Sinus / Q000000981:diagnostic imaging; D005909:Glioblastoma / Q000000981:diagnostic imaging / Q000628:therapy; D006391:Hemangioma / Q000000981:diagnostic imaging; D006801:Humans; D033162:Incidental Findings; D008297:Male; D008577:Meningeal Neoplasms / Q000150:complications / Q000000981:diagnostic imaging; D008579:Meningioma / Q000150:complications / Q000000981:diagnostic imaging; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D018306:Neurocytoma / Q000000981:diagnostic imaging / Q000628:therapy; D010255:Paranasal Sinus Neoplasms / Q000000981:diagnostic imaging; D010300:Parkinson Disease / Q000150:complications / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000235:genetics; D020734:Parkinsonian Disorders / Q000000981:diagnostic imaging* / Q000209:etiology; D010871:Pinealoma / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D017729:Presynaptic Terminals / Q000000981:diagnostic imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012189:Retrospective Studies
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine